U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Sources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

CNS Active
3913
Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Smithson, R.
38
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Activator
1430
Activator
1430
Hydrolytic Enzyme
38
ultraviolet B-induced damage
38
Target ID: ultraviolet B-induced damage
Interacts
323
Activator
1430
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8429
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
Approved
8429
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
Approved
8429
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8429
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.
1993 Aug
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994 Dec
New applications for the zinc iodide-osmium tetroxide technique.
1994 Feb
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.
1997 May 16
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.
2002 Mar 1
Thermotoga maritima-Escherichia coli chimeric topoisomerases. Answers about involvement of the carboxyl-terminal domain in DNA topoisomerase I-mediated catalysis.
2004 Jul 16
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.
2004 Jul 16
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.
2004 Jul 30
High-throughput computational and experimental techniques in structural genomics.
2004 Oct
Impact of the mother's zinc deficiency on the woman's and newborn's health status.
2005
[Zinc and aluminum concentrations in blood of hemodialysis patients and its impact on the frequency of infections].
2005
Zinc in attention-deficit/hyperactivity disorder.
2005 Aug
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.
2005 Aug
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.
2005 Nov-Dec
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.
2005 Sep 1
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.
2006 Apr
Copper and zinc concentrations in serum of healthy Greek adults.
2006 Apr 15
Elevated cortical zinc in Alzheimer disease.
2006 Jul 11
The effect of Ramadan on maternal nutrition and composition of breast milk.
2006 Jun
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.
2006 May
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
On the mechanism of the conversion of methanol to 2,2,3-trimethylbutane (triptane) over zinc iodide.
2006 Nov 10
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.
2010 Jan 12
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.
2011 Nov 30
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Inorganic salts in atmospheric particulate matter: Raman spectroscopy as an analytical tool.
2013 Nov
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013 Sep
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.
2014 Nov 4
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.
2015 Apr 2
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.
2015 Jan 25
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Substance Class Protein
Created
by admin
on Sat Dec 16 01:41:01 GMT 2023
Edited
by admin
on Sat Dec 16 01:41:01 GMT 2023
Protein Sub Type
Sequence Type COMPLETE
Record UNII
2GFP9BJD79
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLUCARPIDASE
DASH   INN   VANDF   WHO-DD  
INN  
Official Name English
VORAXAZE
Brand Name English
PTEROYLMONOGLUTAMIC ACID HYDROLASE G2
Common Name English
glucarpidase [INN]
Common Name English
FOLATE HYDROLASE G2
Common Name English
CARBOXYPEPTIDASE G2
Common Name English
CPG2
Common Name English
Glucarpidase [WHO-DD]
Common Name English
GLUCARPIDASE [VANDF]
Common Name English
GLUCARPIDASE [MI]
Common Name English
GLUCARPIDASE [JAN]
Common Name English
.GAMMA.-GLU-X CARBOXYPEPTIDASE
Common Name English
GLUCARPIDASE [PURPLE BOOK CDER]
Common Name English
RECOMBINANT GLUTAMATE CARBOXYPEPTIDASE (CARBOXYPEPTIDASE G2)
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/02/128
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
WHO-VATC QV03AF09
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
NCI_THESAURUS C29726
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
NDF-RT N0000184013
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
WHO-ATC V03AF09
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
FDA ORPHAN DRUG 163702
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
Code System Code Type Description
DAILYMED
2GFP9BJD79
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
IUPHAR
7450
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
EVMPD
SUB25203
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
ChEMBL
CHEMBL1863515
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
RXCUI
1242127
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY RxNorm
DRUG CENTRAL
5138
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
PUBCHEM
21195079
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
MERCK INDEX
m11689
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
ECHA (EC/EINECS)
232-978-1
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
CAS
9074-87-7
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
DRUG BANK
DB08898
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
NCI_THESAURUS
C346
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
NDF-RT
N0000167577
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY Carboxypeptidases [Chemical/Ingredient]
FDA UNII
2GFP9BJD79
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
WIKIPEDIA
Glucarpidase
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
INN
8509
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
Related Record Type Details
GLUCARPIDASE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:ESTIMATE CHEMICAL
Biological Half-life PHARMACOKINETIC
Molecular Formula CHEMICAL
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966